Melinta Therapeutics has reported top-line results from the second Phase 3 study of Baxdela (delafloxacin), an investigational anionic quinolone in development for the treatment of patients with acute bacterial skin and skin structure infections. Baxdela met the primary endpoints required by the U.S. Food and Drug Administration as well as the European Medicines Agency.

“Baxdela’s breadth of activity against difficult pathogens and in difficult patients, together with the favorable safety profile observed to date, and IV-to-oral dosing flexibility, should prove to be a valuable addition to the dwindling arsenal of antibiotics for serious infections,” commented Chief Executive Officer Eugene Sun, MD.